Moreover, thanks to the large amount of participants included in the BioFINDER-2 study, we can now fully confirm and expand previous findings, by showing that the variance in plasma NTA-tau levels is mainly associated with the tau-PET signal, even when adjusting for CSF Aβ42/40, which supports the claim of NTA-tau being specifically associated with insoluble tau deposition in AD. Here, MAPT is linked to Alzheimer disease.